TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04465318

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarette (EC)
Description: NJOY Daily E-cigarettes are self-contained and non-refillable. Each DAILY provides approximately 300 puffs, comparable to a full pack of cigarettes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT)
Description: Participants in the NRT arm will receive 21 mg nicotine patch (for those with CPD \>= 20) or 14 mg nicotine patch (for those with CPD \< 20) + 4 mg nicotine gum. CPD stands for Cigarettes Per Day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Harm Reduction Counseling Sessions
Description: Counseling will cover health education, social support issues, and motivational enhancement to improve self-efficacy while addressing other aspects know to contribute to smoking among people with COPD (e.g., tips on dealing with depression)
Study: NCT01590810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for MK-8150
Description: Single oral dose-matched dose of Placebo for MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8150 50 mg
Description: Single oral 50-mg dose of MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8150 100 mg
Description: Single oral 100-mg dose of MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8150 200 mg
Description: Single oral 200-mg dose of MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8150 400 mg
Description: Single oral 400-mg dose of MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8150 500 mg
Description: Single oral 500-mg dose of MK-8150
Study: NCT04465318

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Harm Reduction Counseling Sessions
Description: Counseling will cover health education, social support issues, and motivational enhancement to improve self-efficacy while addressing other aspects know to contribute to smoking among people with COPD (e.g., tips on dealing with depression)
Study: NCT02993042

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training
Description: Patients should use their belts (Harness) to support their weight when walking in equipment. In the first training session, the patient focuses on fitting and adapting the equipment and helps the patient learn. To minimize skin damage, the patient can wear a protector. The initial walking speed starts at 1.5km / h (0.42m / s) and can be increased gradually to 3.0km / h (0.83m / s) by increasing to 0.2km / h (0.06m / s) per session. The therapist provides appropriate visual and auditory instructions to allow the patient to participate as fully as possible in the walking cycle provided by the walking robot. The treatment time per session is 30 minutes except for the time of wearing and releasing.
Study: NCT01971268

Intervention type: DEVICE
Intervention: Dental Implant
Description: place dental implants according to manufacturer guidelines

Intervention type: DEVICE
Intervention: Dental Implant
Description: place dental implants according to manufacturer guidelines

Intervention type: DEVICE
Intervention: Platform-Switch Dental Implant
Description: Place Dental Implant with an abutment narrower than the implant platform
Study: NCT00890396

Intervention type: DRUG
Intervention: Hydroxyurea
Description: Parents and child's doctor may plan to use or not to use hydroxyurea.

Intervention type: DRUG
Intervention: Hydroxyurea
Description: Parents and child's doctor may plan to use or not to use hydroxyurea.
Study: NCT02035410

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hydrogen peroxide pretreatment group
Description: Hydrogen peroxide pretreatment perform before cardiac devices Implantation. It disinfects the cardiac devices pocket using Hydrogen peroxide gauze.
Study: NCT02205177

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mayo Clinic Anxiety Coach
Description: Mayo Clinic Anxiety Coach is a smartphone application based on cognitive-behavioral treatment for anxiety disorders (i.e., exposure-based therapy) that can be used as 1) a stand-alone treatment requiring minimal provider contact, and 2) an augmentation of face-to-face treatment that increases clinician fidelity and patient adherence to evidence-based treatment. The design of Anxiety Coach is based on evidence and theory suggesting that information and communication technologies (ICTs) are well-suited for encouraging behavior change through 1) scheduled reminders to engage in therapeutic exercises, 2) point of performance support, 3) individually tailored information, 4) real-time symptom assessment, and 5) readily accessible asynchronous communication.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mayo Clinic Anxiety Coach
Description: Mayo Clinic Anxiety Coach is a smartphone application based on cognitive-behavioral treatment for anxiety disorders (i.e., exposure-based therapy) that can be used as 1) a stand-alone treatment requiring minimal provider contact, and 2) an augmentation of face-to-face treatment that increases clinician fidelity and patient adherence to evidence-based treatment. The design of Anxiety Coach is based on evidence and theory suggesting that information and communication technologies (ICTs) are well-suited for encouraging behavior change through 1) scheduled reminders to engage in therapeutic exercises, 2) point of performance support, 3) individually tailored information, 4) real-time symptom assessment, and 5) readily accessible asynchronous communication.
Study: NCT03289676

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Storytelling Narrative Intervention
Description: In the first phase, three sections of a video, each for 5-7 minutes will be produced by Star story tellers who are eloquent and have authentic personal experiences of quitting smoking. Participants who receive 8-weekly 30-minute cessation counseling sessions along with NRT are randomly assigned to watch either the smoking cessation video or attention-control video of women taking about their HIV infection.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Storytelling Narrative Intervention
Description: In the first phase, three sections of a video, each for 5-7 minutes will be produced by Star story tellers who are eloquent and have authentic personal experiences of quitting smoking. Participants who receive 8-weekly 30-minute cessation counseling sessions along with NRT are randomly assigned to watch either the smoking cessation video or attention-control video of women taking about their HIV infection.
Study: NCT02089191

Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A contact lenses
Study: NCT01044264

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04061811

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic biomarker study
Description: Comparing circulating concentrations of NT-proBNP, GDF15, and neprilysin (NEP) along with NEP activity in patients with and without HF, as diagnosed by clinical parameters and post-dialysis echocardiography.

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic biomarker study
Description: Comparing circulating concentrations of NT-proBNP, GDF15, and neprilysin (NEP) along with NEP activity in patients with and without HF, as diagnosed by clinical parameters and post-dialysis echocardiography.
Study: NCT00961844

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic cells - transfected with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion
Study: NCT01971268

Intervention type: DEVICE
Intervention: Platform-Matched dental implant
Description: Place Dental Implant with abutment with same size as the platform
Study: NCT04301180

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Education food
Description: The intervention consisted of the presentation of food education content while conducting an orchard with seasonal vegetables
Study: NCT02714881

Intervention type: DRUG
Group type: OTHER
Intervention: certolizumab
Description: Subjects who are about to start TNFi therapy as part of usual therapy will be enrolled. In this study we will provide the drug, certolizumab.
Study: NCT02089191

Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Stenfilcon A contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Stenfilcon A contact lenses
Study: NCT03316898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-242071
Description: AGN-242071 capsules administered once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-242071
Description: AGN-242071 capsules administered once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-242071
Description: AGN-242071 capsules administered once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil 10 mg as prescribed by the physician as per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil 10 mg as prescribed by the physician as per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil 10 mg as prescribed by the physician as per standard of care.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil
Description: Donepezil 10 mg as prescribed by the physician as per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Memantine as prescribed by the physician as per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Memantine as prescribed by the physician as per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Memantine as prescribed by the physician as per standard of care.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Memantine
Description: Memantine as prescribed by the physician as per standard of care.
Study: NCT01314885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03715455
Description: 20mg, Inhaled, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: 30mg, Oral, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for PF-03715455
Description: Single dose, inhaled, Placebo for PF-03715455

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for PH-797804
Description: Single Dose, Oral, Placebo for PH-797804
Study: NCT04604015

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: NeuralBot Investigational System
Description: The NeuralBot Investigational System when used with the Lucid M1 System is a medical ultrasound device which assists the user in the setup and acquisition of cerebral blood flow velocity via the patient's temporal windows. It is intended for use as an adjunct to standard clinical practices for measuring and displaying cerebral blood flow velocity and the occurrence of transient emboli within the blood stream.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transthoracic Echocardiography (TTE)
Description: A test that uses ultrasound to create a hemodynamic assessment for major cardiovascular events.
Study: NCT01753843

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: early cord clamping
Description: early ( \<20 seconds)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brief Delay in cord clamping
Description: delay in cord clamping 30 to 60 seconds
Study: NCT04262674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive-motor training
Description: Simultaneous cognitive-motor training and strength training
Study: NCT01078181

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gastric bypass
Description: laparoscopic gastric bypass with circular stapled 21mm gastrojejunostomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gastric bypass
Description: laparoscopic gastric bypass with circular stapled 21mm gastrojejunostomy
Study: NCT02899026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab
Description: Sirukumab will be provided as 1 millilitre (mL) Pre-filled Syringe (PFS), containing 100 mg/mL or 50 mg/mL of sirukumab, fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab
Description: Sirukumab will be provided as 1 millilitre (mL) Pre-filled Syringe (PFS), containing 100 mg/mL or 50 mg/mL of sirukumab, fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug
Study: NCT02714881

Intervention type: RADIATION
Group type: OTHER
Intervention: Stress myocardial perfusion PET
Description: We will measure coronary flow reserve (CFR) using cardiac PET before the patients starts TNFi and 24 weeks after starting TNFi.
Study: NCT02119156

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Belimumab
Description: Monthly intravenous infusions dosed as 10 mg/kg body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Monthly intravenous infusions dosed as 10 mg/kg body weight
Study: NCT03384823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938
Description: Subjects will receive either a single dose of EDP-938 on Day 1 only (SAD) or a single dose of EDP-938 starting on Day 1 through Day 7 (MAD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938
Description: Subjects will receive either a single dose of EDP-938 on Day 1 only (SAD) or a single dose of EDP-938 starting on Day 1 through Day 7 (MAD).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo to match EDP-938

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo to match EDP-938
Study: NCT04142151

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sanchitongshu
Description: SanchiTongshu capsule produced by Chengdu Huashen Group Co., Ltd.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: Aspirin produced by Bayer Co., Ltd.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin produced by Bayer Co., Ltd.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel produced by Shenzhen Salubris Co., Ltd.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel produced by Shenzhen Salubris Co., Ltd.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo of Sanchitongshu
Description: SanchiTongshu palcebo capsule contained dark brown muscovada sugar and the same inactive excipient (starch). Produced by Chengdu Huashen Group Co., Ltd.
Study: NCT03071484

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: The tDCS is a non-invasive neuromodulatory technique that delivers low-intensity, direct current to cortical areas facilitating or inhibiting spontaneous neuronal activity.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: The tDCS is a non-invasive neuromodulatory technique that delivers low-intensity, direct current to cortical areas facilitating or inhibiting spontaneous neuronal activity.
Study: NCT03418558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Study: NCT01519999

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared Decision Making for Colorectal Cancer Screening
Description: Age-eligible adults in the intervention communities will be exposed to the shared decision-making intervention when they are seen in the primary care clinics (N=all patients 50-75 years seen during the study period who are non-adherent to CRCS recommendation). Additionally, among patients with primary care visits scheduled one week or more before the visit, they will be randomized to receive either a mailed decision aid booklet or an informational flyer on shared decision making and CRCS prior to the visit. Patients with primary care visits scheduled less than one week prior to the visit will not be mailed materials in advance. The effect of the pre-visit materials on referral to SDM session and CRCS adherence between these groups will be compared. They will also be exposed to shared decision-making tools and resources available through the community-wide intervention activities.
Study: NCT02421263

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin
Description: Participants will receive 20 mg/70 kg of psilocybin in the first session and will receive either 20 or 30 mg/70 kg in the second session.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Participants will receive 20 mg/70 kg of psilocybin in the first session and will receive either 20 or 30 mg/70 kg in the second session.
Study: NCT03201692

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Treadmill Training
Description: Subjects in the experimental group will receive 40 minutes comprising exercises focused on improving dynamic balance following auditory and visual cues.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill training
Description: Subjects in the active comparator group will receive 40 minutes walking training aimed to improve velocity and endurance.
Study: NCT00214474

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ATSM Intervention
Description: Participants randomized to ATSM Intervention received weekly, automated (pre-recorded) telephone calls over 39 weeks (9 months). Patient responses triggered either immediate, automated health education messages and/or subsequent nurse phone follow-up.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GMV Intervention
Description: GMV Intervention involved 90-minute monthly sessions over 9 months, involving 6-10 participants, co-facilitated by a primary care physician and health educator.
Study: NCT02317809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liquid pergoveris
Description: All subjects will be administered with 900 IU of r-hFSH and 450 IU of r-hLH solution (Liquid Pergoveris) as subcutaneous injection using a disposable pen-injector on Day 1 in either first intervention period or second intervention period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liquid pergoveris
Description: All subjects will be administered with 900 IU of r-hFSH and 450 IU of r-hLH solution (Liquid Pergoveris) as subcutaneous injection using a disposable pen-injector on Day 1 in either first intervention period or second intervention period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Freeze-dried pergoveris
Description: All subjects will be administered with 900 IU of r-hFSH and 450 IU of r-hLH freeze-dried powder (Freeze-dried Pergoveris) as subcutaneous injection on Day 1 in either first intervention period or second intervention period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Freeze-dried pergoveris
Description: All subjects will be administered with 900 IU of r-hFSH and 450 IU of r-hLH freeze-dried powder (Freeze-dried Pergoveris) as subcutaneous injection on Day 1 in either first intervention period or second intervention period.
Study: NCT03606772

Intervention type: OTHER
Intervention: Questionanniare
Description: Filling printed questionnaire + Pelvic examination
Study: NCT01338870

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets (n=4), 0 mg twice daily for 84 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg PF-04991532
Description: Tablets (n=1), 25 mg strength + tablets (n=3) 0 mg twice daily for 84 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75 mg PF-04991532
Description: Tablets (n=3), 25 mg strength + tablets (n=1) 0 mg twice daily for 84 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg PF-04991532
Description: Tablets (n=1), 150 mg strength + tablets (n=3) 0 mg twice daily for 84 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 mg PF-04991532
Description: Tablets (n=2), 150 mg strength + tablets (n=2) 0 mg twice daily for 84 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100 mg
Description: Tablets (n=1), 100 mg strength + tablets (n=3) 0 mg once daily in the morning for 84 days; and tablets (n=4) 0 mg once daily in the evening for 84 days.